Monopar Therapeutics Inc. (MNPR) Operating income 2016–2025
Monopar Therapeutics Inc. (MNPR) annual operating income history from SEC filings — each fiscal year as reported.
-$16.7MFY2025 · since FY2016: -$1.2M → -$16.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$16.7M | -3.4% |
| FY2024 | -$16.2M | -83.0% |
| FY2023 | -$8.8M | +16.2% |
| FY2022 | -$10.5M | -15.4% |
| FY2021 | -$9.1M | -40.2% |
| FY2020 | -$6.5M | -50.5% |
| FY2019 | -$4.3M | -29.8% |
| FY2018 | -$3.3M | +79.9% |
| FY2017 | -$16.6M | -1291.9% |
| FY2016 | -$1.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More MNPR financial trends
MNPR RevenueMNPR Net incomeMNPR Net marginMNPR Gross profitMNPR Gross marginMNPR Operating marginMNPR Operating cash flowMNPR Free cash flowMNPR Capital expendituresMNPR Return on equityMNPR Stock buybacksMNPR Dividends paidMNPR Total assetsMNPR Total liabilitiesMNPR Shareholders’ equityMNPR overview →